Submitted by web@researchtop... on Fri, 01/27/2012 - 16:31
Submitted by web@researchtop... on Fri, 01/27/2012 - 10:48
Submitted by mphilemon@resea... on Tue, 01/17/2012 - 13:49
Submitted by web@researchtop... on Tue, 01/10/2012 - 14:12
Submitted by web@researchtop... on Fri, 01/06/2012 - 14:42
Submitted by web@researchtop... on Tue, 01/03/2012 - 08:42
Submitted by web@researchtop... on Fri, 12/30/2011 - 15:29
Submitted by mphilemon@resea... on Thu, 12/22/2011 - 13:59
Faculty Comments on Anti-Angiogenesis in Gastric Cancer
In light of the AVAGAST trial data, do you expect that bevacizumab and newer-generation anti-angiogenic agents, such as ramucirumab, will play a significant role in the treatment of metastatic gastric cancer?
Submitted by web@researchtop... on Mon, 12/19/2011 - 15:42
Submitted by web@researchtop... on Wed, 12/14/2011 - 09:40
Submitted by web@researchtop... on Mon, 12/05/2011 - 14:39
Select review papers on hepatocellular carcinoma
El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365(12):1118-27. Abstract
Kim R et al. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. Oncology (Williston Park) 2011;25(3):283-91, 295. Abstract
Van Malenstein H et al. Molecular classification of hepatocellular carcinoma anno 2011. Eur J Cancer 2011;47(12):1789-97. Abstract
Submitted by web@researchtop... on Mon, 12/05/2011 - 14:37
Two interesting reports on outcomes for patients with HCC who received liver transplants
Åberg F et al. Long-term results of liver transplantation. Scand J Surg 2011;100(1):14-21. Abstract
Masuoka HC, Rosen CB. Liver transplantation for hepatocellular carnicoma: Expanding frontiers and building bridges. Clin Liver Dis 2011;15(2):385-93. Abstract
Submitted by web@researchtop... on Fri, 12/02/2011 - 11:00
Submitted by web@researchtop... on Thu, 12/01/2011 - 18:21
Submitted by mphilemon@resea... on Wed, 11/23/2011 - 11:57